{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:24:55Z","timestamp":1793064295448,"version":"4.5.0"},"reference-count":467,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T00:00:00Z","timestamp":1397692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.euroneuro.2014.03.008","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T03:00:16Z","timestamp":1396580416000},"page":"645-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":322,"title":["Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment"],"prefix":"10.1016","volume":"24","author":[{"given":"Mark J.","family":"Millan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Fone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Horan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.03.008_bib1","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.biopsych.2010.09.022","article-title":"Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology","volume":"68","author":"Abazyan","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00001756-200303030-00018","article-title":"Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study","volume":"14","author":"Abel","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1146\/annurev.psych.60.110707.163514","article-title":"The social brain: neural basis of social knowledge","volume":"60","author":"Adolphs","year":"2009","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.9758\/cpn.2013.11.3.118","article-title":"Transcranial direct current stimulation in schizophrenia","volume":"11","author":"Agarwal","year":"2013","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/hup.1246","article-title":"The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study","volume":"26","author":"Ahn","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib7","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neuropharm.2011.11.008","article-title":"Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia","volume":"62","author":"Alberati","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00213-011-2539-2","article-title":"Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the \u03b17 positive modulator galantamine","volume":"220","author":"Alexander","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pnpbp.2012.10.024","article-title":"Cannabidiol exhibits anxiolytic but not antipsychotic properties evaluated in the social interaction test","volume":"41","author":"Almeida","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia. Definition and reliability","volume":"39","author":"Andreasen","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl. November","key":"10.1016\/j.euroneuro.2014.03.008_bib12","first-page":"238","article-title":"The scale for the assessment of negative symptoms (SANS): conceptual and theroretical foundations","volume":"S7","author":"Andreasen","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib13","doi-asserted-by":"crossref","unstructured":"Andreassen, O.A., Harbo, H.F., Wang, Y., Thompson, W.K., Schork, A.J., Mattingsdal, M., Zuber, V., Bettella, F., Ripke, S., Kelsoe, J.R., Kendler, K.S., O\u2019Donovan, M.C., Sklar, P., Psychiatric Genomics Consortium (PGC) Bipolar Disorder Schizophrenia Work Groups. International Multiple Sclerosis Genetics Consortium (IMSGC), McEvoy, L.K., Desikan, R.S., Lie, B.A., Djurovic, S., Dale, A.M., 2014. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol. Psychiatry, 10.1038\/mp.2013.195","DOI":"10.1038\/mp.2013.195"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.schres.2013.07.026","article-title":"Pharmacological approaches to treating negative symptoms: a review of clinical trials","volume":"150","author":"Arango","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib15","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1586\/ern.09.152","article-title":"Neurodegeneration in schizophrenia","volume":"10","author":"Archer","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib16","first-page":"CD006633","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","author":"Asenjo-Lobos","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib17","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0006-3223(98)00266-2","article-title":"Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology","volume":"45","author":"Baar\u00e9","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/schbul\/sbq098","article-title":"Neonatal behavioral changes in rats with gestational exposure to lipopolysaccharide: a prenatal infection model for developmental neuropsychiatric disorders","volume":"38","author":"Baharnoori","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pbb.2007.08.011","article-title":"Behavioral processes mediating phencyclidine-induced decreases in voluntary sucrose consumption","volume":"88","author":"Baird","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.186.2.115","article-title":"Adolescents and young adults with 22q11 deletion syndrome: psychopathology in an at-risk group","volume":"186","author":"Baker","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib21","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.euroneuro.2012.03.006","article-title":"Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia","volume":"22","author":"Balla","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2013.04.027","article-title":"Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5","volume":"150","author":"Barch","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/schbul\/sbq068","article-title":"Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions","volume":"36","author":"Barch","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1037\/a0014625","article-title":"Dopamine modulates effort-based decision making in rats","volume":"123","author":"Bardgett","year":"2009","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.brs.2011.06.003","article-title":"A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia","volume":"5","author":"Barr","year":"2012","journal-title":"Brain Stimul."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.euroneuro.2013.10.001","article-title":"Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia","volume":"24","author":"Barnes","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib27","doi-asserted-by":"crossref","unstructured":"Barsaglini, A., Sartori, G., Benetti, S., Pettersson-Yeo,W., Mechelli, A., 2014. The effects of psychotherapy on brain function: a systematic and critical review. Progr. Neurobiol. 10.1016\/j.pneurobio.2013.10.006","DOI":"10.1016\/j.pneurobio.2013.10.006"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/schbul\/sbr040","article-title":"Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia","volume":"39","author":"Beck","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/0019-5545.111445","article-title":"Dorsolateral prefrontal lobe volume and neurological soft signs as predictors of clinical social and functional outcome in schizophrenia: a longitudinal study","volume":"55","author":"Behere","year":"2013","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fpsyt.2012.00042","article-title":"The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: a voxel-based morphometry study","volume":"3","author":"Benoit","year":"2012","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0447.2010.01635.x","article-title":"Gray matter volume deficits and correlation with insight and negative symptoms in first-psychotic-episode subjects","volume":"123","author":"Berg\u00e9","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2012.09.025","article-title":"Clinical utility of transcranial direct current stimulation (tDCS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials","volume":"47","author":"Berlim","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.conb.2013.01.017","article-title":"Neuroscience of affect: brain mechanisms of pleasure and displeasure","volume":"23","author":"Berridge","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coph.2008.12.014","article-title":"Dissecting components of reward: liking, wanting, and learning","volume":"9","author":"Berridge","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hipo.20628","article-title":"Longitudinal MRI monitoring of brain damage in the neonatal ventral hippocampal lesion rat model of schizophrenia","volume":"20","author":"Bertrand","year":"2010","journal-title":"Hippocampus"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.schres.2010.08.003","article-title":"Vocational rehabilitation improves cognition and negative symptoms in schizophrenia","volume":"126","author":"Bio","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/schbul\/sbj013","article-title":"The structure of negative symptoms within schizophrenia: implications for assessment","volume":"32","author":"Blanchard","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib38","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/schbul\/sbq104","article-title":"Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia","volume":"37","author":"Blanchard","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2014.01.010","article-title":"Social cognition and neurocognitive deficits in first-episode schizophrenia","volume":"153","author":"Bliksted","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib40","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/schbul\/sbm052","article-title":"Spontaneous low-frequency fluctuations in the BOLD signal in schizophrenic patients: anomalies in the default network","volume":"33","author":"Bluhm","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2012.08.017","article-title":"Duration of untreated psychosis and negative symptoms \u2013 a systematic review and meta-analysis of individual patient data","volume":"142","author":"Boonstra","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pscychresns.2010.12.004","article-title":"How can cognitive remediation therapy modulate brain activation in schizophrenia? An fMRI study","volume":"192","author":"Bor","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.12.020","article-title":"Theory of mind impairment in schizophrenia: meta-analysis","volume":"109","author":"Bora","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib44","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4088\/JCP.v64n0816","article-title":"Negative symptoms in depressed and schizophrenic patients: how do they differ?","volume":"64","author":"Bottlender","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3758\/CABN.9.1.16","article-title":"Effort discounting in human nucleus accumbens","volume":"9","author":"Botvinick","year":"2009","journal-title":"Cogn. Affect. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib46","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.neuropharm.2004.02.008","article-title":"SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats","volume":"46","author":"Boulay","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib47","first-page":"1","article-title":"Negative symptoms in schizophrenia: a comprehensive review of electrophysiological investigations","volume":"21","author":"Boutros","year":"2013","journal-title":"Clin. Schizophr. Relat. Psychos."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2014.01.015","article-title":"While matter pathway organization of the reward system is related to positive and negative symptoms in schizophrenia","volume":"153","author":"Bracht","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00213-008-1195-7","article-title":"Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia","volume":"200","author":"Brady","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib50","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1176\/appi.ajp.160.8.1413","article-title":"Is regionally selective D2\/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123l]epidepride SPECT study of amisulpride-treated patients","volume":"160","author":"Bressan","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2013.04.026","article-title":"A schizophrenia rat model induced by early postnatal phencyclidine treatment and characterized by magnetic resonance imaging","volume":"250","author":"Broberg","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib52","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00213-014-3459-8","article-title":"\u03b12-adrenoceptors are targets for antipsychotic drugs","volume":"231","author":"Brosda","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/ern.11.183","article-title":"Potential therapeutic avenues to tackle social cognition problems in schizophrenia","volume":"12","author":"Brown","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib54","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neubiorev.2008.09.002","article-title":"Default-mode brain dysfunction in mental disorders: a systematic review","volume":"33","author":"Broyd","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/schbul\/sbi002","article-title":"\u201cTheory of mind\u201d in schizophrenia: a review of the literature","volume":"31","author":"Br\u00fcne","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib56","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1176\/appi.ajp.2012.11071091","article-title":"Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia","volume":"169","author":"Brunelin","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib57","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","article-title":"Persistent negative symptoms in schizophrenia: an overview","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib58","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.biopsych.2010.09.052","article-title":"A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia","volume":"69","author":"Buchanan","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib59","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/schbul\/sbq038","article-title":"The FDA-NIMH-MATRICS guideline for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?","volume":"37","author":"Buchanan","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JCP.0b013e31823f880a","article-title":"Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia","volume":"32","author":"Buchanan","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1037\/0021-843X.116.1.30","article-title":"Anhedonia and the experience of emotion in individuals with schizophrenia","volume":"116","author":"Burbridge","year":"2007","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainresbull.2013.05.003","article-title":"d-Cycloserine improves sociability in the BTBR T+ Itpr3tf\/J mouse model of autism spectrum disorders with altered Ras\/Raf\/ERK1\/2 signaling","volume":"96","author":"Burket","year":"2013","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainresbull.2013.11.005","article-title":"Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)\/J mouse model of autism spectrum disorders","volume":"100","author":"Burket","year":"2014","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib65","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.neuron.2010.03.010","article-title":"Primate social cognition: uniquely primate, uniquely social, or just unique?","volume":"65","author":"Byrne","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib66","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0006-3223(99)00088-8","article-title":"Deficit psychopathology and a paradigm shift in schizophrenia research","volume":"46","author":"Carpenter","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib67","first-page":"5878","article-title":"Deficit and nondeficit forms of schizophrenia: the concept","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib1002","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/hbm.20671","article-title":"Are there theory of mind regions in the brain? A review of the neuroimaging literature","volume":"30","author":"Carrington","year":"2009","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib68","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/schbul\/sbm081","article-title":"Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative","volume":"33","author":"Carter","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2010.03.039","article-title":"Gray-matter abnormalities in deficit schizophrenia","volume":"120","author":"Cascella","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib70","first-page":"89","article-title":"Preclinical behavioral models for predicting antipsychotic activity","volume":"57","author":"Castagn\u00e9","year":"2009","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib71","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia","volume":"79","author":"Ceccarini","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib72","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuropharm.2011.06.014","article-title":"Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats","volume":"62","author":"Chartoff","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib73","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12640-010-9196-9","article-title":"Apathy in neuropsychiatry disease: diagnosis, pathophysiology, and treatment","volume":"19","author":"Chase","year":"2011","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib74","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00702-009-0255-4","article-title":"Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia","volume":"116","author":"Chertkow","year":"2009","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib75","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/syn.20857","article-title":"Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia","volume":"65","author":"Chin","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-642-25758-2_4","article-title":"Towards medication-enhancement of cognitive interventions in schizophrenia","volume":"213","author":"Chou","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib77","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.yhbeh.2011.12.003","article-title":"Modulating social behavior with oxytocin: how does it work? What does it mean?","volume":"61","author":"Churchland","year":"2012","journal-title":"Horm. Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib78","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-013-0105-7","article-title":"A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach","volume":"27","author":"Citrome","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-012-2845-3","article-title":"Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine","volume":"225","author":"Clifton","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib1001","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/schbul\/sbl066","article-title":"Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date","volume":"33","author":"Cohen","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib80","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/FBP.0b013e328363d14a","article-title":"The utility of the zebrafish model in conditioned place preference to assess the rewarding effects of drugs","volume":"24","author":"Collier","year":"2013","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib81","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1017\/S0033291710000802","article-title":"The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis","volume":"41","author":"Corcoran","year":"2011","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib82","first-page":"501726","article-title":"Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use","volume":"2011","author":"Coulston","year":"2011","journal-title":"Schizophr. Res. Treat."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib83","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-3-642-25758-2_10","article-title":"Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications","volume":"213","author":"Coyle","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib84","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1523\/JNEUROSCI.4515-08.2009","article-title":"Effort-based cost-benefit valuation and the human brain","volume":"29","author":"Croxson","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib85","doi-asserted-by":"crossref","first-page":"e002542","DOI":"10.1136\/bmjopen-2012-002542","article-title":"Does cognitive behavior therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis","volume":"3","author":"Cuijpers","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib86","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/wps.20087","article-title":"The RDoC framework: facilitating transition from ICD\/DSM to dimensional approaches that integrate neuroscience and psychopathology","volume":"13","author":"Cuthbert","year":"2014","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib87","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2013.04.023","article-title":"Effects of single dose intranasal oxytocin on social cognition in schizophrenia","volume":"147","author":"Davis","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib88","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.euroneuro.2013.10.010","article-title":"Psychopharmacology of the negative symptoms: Current status and prospects for progress","volume":"24","author":"Davis","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib89","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2165\/11632000-000000000-00000","article-title":"Minocycline: therapeutic potential in psychiatry","volume":"26","author":"Dean","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2012.02.033","article-title":"Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia","volume":"682","author":"De Bartolomeis","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib91","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/1871527311312020012","article-title":"The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review","volume":"12","author":"De Berardis","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib92","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0028-3908(99)00268-3","article-title":"Citalopram reduces social interaction in rats by activation of serotonin 5-HT2C receptors","volume":"39","author":"Dekeyne","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib93","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00213-008-1177-9","article-title":"S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models","volume":"199","author":"Dekeyne","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib94","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/schbul\/sbq088","article-title":"Disorganization\/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis","volume":"38","author":"Demjaha","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib95","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tins.2011.11.005","article-title":"The neurobiology of anhedonia and other reward-related deficits","volume":"35","author":"Der-Avakian","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib96","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbi.2012.02.010","article-title":"Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene\u00d7environment interaction","volume":"26","author":"Desbonnet","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib97","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fpsyt.2013.00172","article-title":"Reinforcement learning and dopamine in schizophrenia: dimensions of symptoms or specific features of a disease group?","volume":"4","author":"Deserno","year":"2013","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib98","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.neuropsychologia.2012.02.007","article-title":"The role of the human ventral striatum and the medial orbifrontal cortex in the representation of reward magnitude \u2013 an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing","volume":"50","author":"Diekhof","year":"2012","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib99","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/schbul\/sbp115","article-title":"The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements","volume":"36","author":"Dixon","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib100","doi-asserted-by":"crossref","first-page":"e76655","DOI":"10.1371\/journal.pone.0076655","article-title":"Neuroimaging evidence of major morpho-anatomical and functional abnormalities in the BTBR T+TF\/J mouse model of autism","volume":"8","author":"Dodero","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib101","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.euroneuro.2013.03.001","article-title":"Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials","volume":"23","author":"Dold","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature12518","article-title":"Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin","volume":"501","author":"D\u00f6len","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib103","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.neuroscience.2007.02.046","article-title":"Alkmaion\u05f3s discovery that brain creates mind: a revolution in human knowledge comparable to that of Copernicus and of Darwin","volume":"147","author":"Doty","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib104","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.biopsych.2009.10.020","article-title":"Anhedonia and emotional experience in schizophrenia: neural and behavioral indicators","volume":"67","author":"Dowd","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib105","doi-asserted-by":"crossref","first-page":"e35622","DOI":"10.1371\/journal.pone.0035622","article-title":"Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia","volume":"7","author":"Dowd","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib106","doi-asserted-by":"crossref","first-page":"7731","DOI":"10.1523\/JNEUROSCI.1736-07.2007","article-title":"Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing","volume":"27","author":"Drew","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib107","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neubiorev.2008.07.001","article-title":"The social role of touch in humans and primates: behavioural function and neurobiological mechanisms","volume":"34","author":"Dunbar","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib108","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S003329171100119X","article-title":"Striatal function in relation to negative symptoms in schizophrenia","volume":"42","author":"Ehrlich","year":"2012","journal-title":"Psychol. Med."},{"issue":"33","key":"10.1016\/j.euroneuro.2014.03.008_bib109","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cpr.2013.07.001","article-title":"Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions","volume":"2013","author":"Elis","year":"2013","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.neuroimage.2012.12.029","article-title":"Neuroanatomical analysis of the BTBR mouse model of autism using magnetic resonance imaging and diffusion tensor imaging","volume":"70","author":"Ellegood","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pscychresns.2005.06.003","article-title":"Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study","volume":"140","author":"Fahim","year":"2005","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib112","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.schres.2011.12.009","article-title":"Is it possible to have impaired neurocognition but good social cognition in schizophrenia?","volume":"135","author":"Fanning","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib113","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/schbul\/sbn187","article-title":"The neurodevelopmental hypothesis of schizophrenia, revisited","volume":"35","author":"Fatemi","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib114","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.biopsych.2010.04.039","article-title":"Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients","volume":"68","author":"Feifel","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/138161211795049633","article-title":"Recent advances in the discovery of d-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia","volume":"17","author":"Ferraris","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib116","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jpsychires.2013.08.003","article-title":"Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-marking","volume":"47","author":"Fervaha","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib117","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3174\/ajnr.A3583","article-title":"Patterns of brain structural changes in first-contact, antipsychotic drug-na\u00efve patients with schizophrenia","volume":"35","author":"Filippi","year":"2014","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib118","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.schres.2012.01.030","article-title":"Cortical structural abnormalities in deficit versus nondeficit schizophrenia","volume":"136","author":"Fischer","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib119","first-page":"127","article-title":"Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls","volume":"7","author":"Fischer-Shoffy","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.neuron.2010.03.011","article-title":"Social cognition and the evolution of language: constructing cognitive phylogenies","volume":"65","author":"Fitch","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib121","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.neubiorev.2008.03.003","article-title":"Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders","volume":"32","author":"Fone","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib1003","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/cercor\/bhr130","article-title":"Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex","volume":"22","author":"Fossat","year":"2012","journal-title":"Cereb. Cortex."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib122","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","article-title":"Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders","volume":"24","author":"Foussias","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib123","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/syn.21551","article-title":"Involvement of 5-HT2A receptor and \u03b12-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow","volume":"66","author":"Franberg","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib124","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-psych-120710-100449","article-title":"Mechanisms of social cognition","volume":"63","author":"Frith","year":"2012","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2013.03.024","article-title":"Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms","volume":"147","author":"Fulford","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib126","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamapsychiatry.2013.269","article-title":"The psychosis high-risk state: a comprehensive state-of-the-art review","volume":"70","author":"Fusar-Poli","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib127","doi-asserted-by":"crossref","first-page":"24.1","DOI":"10.1146\/annurev-clinpsy-032813-153645","article-title":"Attenuated psychosis syndrome: ready for DSM-5.1?","volume":"10","author":"Fusar-Poli","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib128","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/schbul\/sbr134","article-title":"Neuroanatomical maps of psychotis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies","volume":"38","author":"Fusar-Poli","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib129","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.neubiorev.2013.06.001","article-title":"Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies","volume":"37","author":"Fusar-Poli","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/schbul\/sbm097","article-title":"Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia","volume":"34","author":"Galderisi","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib131","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1038\/tp.2012.69","article-title":"GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction","volume":"2","author":"Gandal","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib132","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.schres.2007.03.008","article-title":"Anhedonia in schizophrenia: distinction between anticipatory and consummatory pleasure","volume":"93","author":"Gard","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib133","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1037\/a0018932","article-title":"Differential effects on effort discounting induced by inactivation of the nucleus accumbens core or shell","volume":"124","author":"Ghods-Sharifi","year":"2010","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib134","doi-asserted-by":"crossref","first-page":"15425","DOI":"10.1073\/pnas.1312264110","article-title":"Nonhuman primate model of schizophrenia using a noninvasive EEG method","volume":"110","author":"Gil-da-Costa","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib135","first-page":"CD003079","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","volume":"9","author":"Gillies","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib136","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.neuropharm.2011.03.015","article-title":"NMDA receptors, cognition and schizophrenia \u2013 testing the validity of the NMDA receptor hypofunction hypothesis","volume":"62","author":"Gilmour","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib137","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jneumeth.2011.08.040","article-title":"Simultaneous quantification of d- vs l-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: differential modulation by N-methyl-d-aspartate (NMDA) and other pharmacological agents","volume":"202","author":"Gobert","year":"2011","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib138","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.neubiorev.2009.09.004","article-title":"The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question","volume":"34","author":"Goghari","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib139","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biopsych.2012.12.022","article-title":"Negative symptoms of schizophrenia are associated with abnormal effort-cost computations","volume":"74","author":"Gold","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib140","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.conb.2010.08.020","article-title":"Nonapeptide mechanisms of social cognition, behavior and species-specific social systems","volume":"20","author":"Goodson","year":"2010","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib141","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.dcn.2011.07.007","article-title":"Oxytocin and social motivation","volume":"1","author":"Gordon","year":"2011","journal-title":"Dev. Cogn. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib142","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/brain\/awr059","article-title":"Expected value and prediction error abnormalities in depression and schizophrenia","volume":"134","author":"Gradin","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib143","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pscychresns.2012.06.003","article-title":"Salience network-midbrain dysconnectivity and blunted reward signals in schizophrenia","volume":"211","author":"Gradin","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib144","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/archgenpsychiatry.2011.129","article-title":"Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia","volume":"69","author":"Grant","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib145","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/schbul\/sbq171","article-title":"Social cognition in schizophrenia, Part 1: performance across phase of illness","volume":"38","author":"Green","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib146","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/schbul\/sbm145","article-title":"Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities","volume":"34","author":"Green","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib147","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00210-012-0806-3","article-title":"Dopamine D3 receptor antagonism \u2013 still a therapeutic option for the treatment of schizophrenia","volume":"386","author":"Gross","year":"2013","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib148","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hbm.22162","article-title":"Key functional circuitry altered in schizophrenia involves parietal regions associated with sense of self","volume":"35","author":"Guo","year":"2014","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib149","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/archpsyc.64.12.1356","article-title":"Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia","volume":"64","author":"Gur","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib150","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/FBP.0b013e32833fa7df","article-title":"Current pharmacological models of social withdrawal in rats: relevance to schizophrenia","volume":"21","author":"Gururajan","year":"2010","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib151","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1601-183X.2009.00504.x","article-title":"Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia","volume":"8","author":"Halene","year":"2009","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib152","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbr.2013.06.017","article-title":"Pharmacological disruption of mouse social approach behavior: relevance to negative symptoms of schizophrenia","volume":"252","author":"Hanks","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib153","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11920-010-0148-0","article-title":"Assessment of pharmacotherapy for negative symptoms of schizophrenia","volume":"12","author":"Hanson","year":"2010","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib154","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1093\/hmg\/dds180","article-title":"Alterations of social interaction through genetic and environmental manipulation of the 22q11.2 gene Sept5 in the mouse brain","volume":"21","author":"Harper","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib155","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","article-title":"Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis","volume":"157","author":"Hartling","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib156","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/schbul\/sbj011","article-title":"Negative symptoms and cognitive deficits: what is the nature of their relationship?","volume":"32","author":"Harvey","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib157","first-page":"102","article-title":"Relation between emotional face memory and social anhedonia in schizophrenia","volume":"34","author":"Harvey","year":"2009","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib158","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","article-title":"Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders","volume":"263","author":"Hashimoto","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib159","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1192\/bjp.bp.112.112300","article-title":"Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study)","volume":"202","author":"Hastrup","year":"2013","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib160","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/npp.2010.52","article-title":"Prefrontal cortical changes following: cognitive training in patients with chronic schizophrenia: effects of practice, generalization, and specificity","volume":"35","author":"Haut","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib161","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/schbul\/sbr108","article-title":"Bleuler and the neurobiology of schizophrenia","volume":"37","author":"Heckers","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib162","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2013.04.039","article-title":"Structure of the psychotic disorders classification in DSM-5","volume":"150","author":"Heckers","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib163","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-009-1626-0","article-title":"The 5-HT7 receptor and disorders of the nervous system: an overview","volume":"206","author":"Hedlund","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib164","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1749-6632.2009.05149.x","article-title":"Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders","volume":"1187","author":"Heidbreder","year":"2010","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1254\/jphs.12R15CP","article-title":"Behavioral phenotypes in schizophrenic animal models with multiple combinations of genetic and environmental factors","volume":"121","author":"Hida","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib166","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nn.3187","article-title":"Neural encoding of competitive effort in the anterior cingulate cortex","volume":"15","author":"Hillman","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib167","doi-asserted-by":"crossref","first-page":"16628","DOI":"10.1073\/pnas.1308706110","article-title":"Disrupting the clustering of GABAA receptor \u03b12 subunits in the frontal cortex leads to reduced \u03b3-power and cognitive deficits","volume":"110","author":"Hines","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib168","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/mp.2013.92","article-title":"Copy number variation at 22q11.2: from rare variants to common mechanisms of developmental neuropsychiatric disorders","volume":"18","author":"Hiroi","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib169","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1017\/S0033291712000578","article-title":"The causal relationships between neurocognition, social cognition and functional outcome over time in schizophrenia: a latent difference score approach","volume":"42","author":"Hoe","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev.psych.57.102904.190044","article-title":"Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety","volume":"57","author":"Hollon","year":"2006","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib171","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1523\/JNEUROSCI.0910-08.2008","article-title":"Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo","volume":"28","author":"Honey","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib172","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.schres.2011.06.030","article-title":"Development and psychometric validation of the clinical assessment interview for negative symptoms (CAINS)","volume":"132","author":"Horan","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib173","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1037\/a0017510","article-title":"Electrophysiological correlates of emotional responding in schizophrenia","volume":"19","author":"Horan","year":"2010","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib174","doi-asserted-by":"crossref","unstructured":"Hosking, J.G., Cocker, P.J., Winstanley, C.A., 2014. Dissociable contributions of anterior cingulate cortex and basolateral amygdala on a rodent cost\/benefit decision-making task of cognitive effort. Neuropsychopharmacology, 10.1038\/npp.2014.27","DOI":"10.1038\/npp.2014.27"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib175","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-244X-12-224","article-title":"Identifying persistent negative symptoms in first episode psychosis","volume":"12","author":"Hovington","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib176","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1586\/ern.11.173","article-title":"Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia","volume":"12","author":"Hovington","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib177","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/npp.2013.310","article-title":"Chronic and acute intranasal oxytocin produce divergent social effects in mice","volume":"39","author":"Huang","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib178","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/01612840.2013.843222","article-title":"The relationship between anhedonia and positive, negative, and general symptomatology in patients with schizophrenia","volume":"35","author":"Huxley","year":"2014","journal-title":"Issues Ment. Health Nurs."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib179","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1192\/bjp.bp.112.116285","article-title":"Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias","volume":"204","author":"Jauhar","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib180","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-3-642-25758-2_12","article-title":"Glycine transport inhibitors in the treatment of schizophrenia","volume":"213","author":"Javitt","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib181","doi-asserted-by":"crossref","first-page":"S409","DOI":"10.4103\/0019-5545.116318","article-title":"Effect of yoga therapy on plasma oxytocin and facial emotion recognition deficits in patients of schizophrenia","volume":"55","author":"Jayaram","year":"2013","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib182","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0893-133X(97)00034-1","article-title":"Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat","volume":"17","author":"Jentsch","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib183","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.1523\/JNEUROSCI.0118-13.2013","article-title":"Effects of prefrontal cortical inactivation on neural activity in the ventral tegmental area","volume":"33","author":"Jo","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib184","doi-asserted-by":"crossref","first-page":"12462","DOI":"10.1073\/pnas.1307925110","article-title":"Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/npp.2011.199","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia","volume":"37","author":"Jones","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib186","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00213-006-0405-4","article-title":"Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics","volume":"187","author":"Juckel","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib187","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000325912","article-title":"The negative symptoms of schizophrenia: category or continuum?","volume":"44","author":"Kaiser","year":"2010","journal-title":"Psychopathalogy"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib188","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/7854_2010_42","article-title":"Neurocognition in schizophrenia","volume":"4","author":"Kalkstein","year":"2010","journal-title":"Curr. Top Behav. Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2014.03.008_bib189","first-page":"25","article-title":"DISC1 pathway in brain development: exploring therapeutic targets for major psychiatric disorders","volume":"3","author":"Kamiya","year":"2012","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib190","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.11.015","article-title":"Orbitofrontal cortex abnormality and deficit schizophrenia","volume":"143","author":"Kanahara","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib191","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.brainresbull.2010.04.006","article-title":"N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?","volume":"83","author":"Kantrowitz","year":"2010","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib192","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.neuroscience.2009.01.002","article-title":"Phencyclidine affects firing activity of basolateral amygdala neurons related to social behavior in rats","volume":"159","author":"Katayama","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib193","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pscychresns.2009.11.004","article-title":"Bilateral functiona asymmetry disparity in positive and negative schizophrenia revealed by resting-state fMRI","volume":"182","author":"Ke","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib194","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.psychres.2013.12.051","article-title":"Pinocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study","volume":"205","author":"Khodaie-Ardakani","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib195","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10548-013-0306-x","article-title":"Source activation of p300 correlates with negative symptom severity in patients with schizophrenia","volume":"27","author":"Kim","year":"2014","journal-title":"Brain Topogr."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib196","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archpsyc.58.2.165","article-title":"A separate disease within the syndrome of schizophrenia","volume":"58","author":"Kirkpatrick","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib197","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib198","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib199","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/jnr.23089","article-title":"Hypoactivity of the central dopaminergic system and autistic-like behavior induced by a single early prenatal exposure to lipopolysaccharide","volume":"90","author":"Kirsten","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000290040","article-title":"Prenatal lipopolysaccharide reduces social behavior in male offspring","volume":"17","author":"Kirsten","year":"2010","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib201","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/S1461145713000667","article-title":"Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia","volume":"17","author":"Kishi","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib202","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1440-1819.2011.02293.x","article-title":"Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia","volume":"66","author":"Kitis","year":"2012","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib203","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/NMD.0b013e31825bfa1d","article-title":"Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study","volume":"200","author":"Klingberg","year":"2012","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib204","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbr.2009.03.028","article-title":"Behavioral abnormality and pharmacologic response in social isolation-reared mice","volume":"202","author":"Koike","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib205","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jpsychires.2013.05.009","article-title":"Reduced but broader prefrontal activity in patients with schizophrenia during n-back working memory tasks: a multi-channel near-infrared spectroscopy study","volume":"47","author":"Koike","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib206","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.schres.2011.07.003","article-title":"Apathy, cognitive deficits and functional impairment in schizophrenia","volume":"133","author":"Konstantakopoulos","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib207","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.npp.1301133","article-title":"The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats","volume":"32","author":"Koros","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib208","doi-asserted-by":"crossref","DOI":"10.3371\/CSRP.KRBA.013114","article-title":"Adjunctive pregnenolone ameliorates the cognitive deficits in recent-onset schizophrenia","author":"Kreinin","year":"2014","journal-title":"Clin. Schizophr. Relat. Psychos."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib209","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.euroneuro.2013.06.007","article-title":"The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs","volume":"24","author":"Kring","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-clinpsy-050212-185538","article-title":"Emotion deficits in people with schizophrenia","volume":"9","author":"Kring","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib211","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/appi.ajp.2012.12010109","article-title":"The clinical assessment interview for negative symptoms (CAINS): final development and validation","volume":"170","author":"Kring","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib212","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrn1747","article-title":"The human orbitofrontal cortex: linking reward to hedonic experience","volume":"6","author":"Kringelbach","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib213","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/brain\/awr154","article-title":"Neural changes following cognitive behaviour therapy for psychosis: a longitudinal study","volume":"134","author":"Kumari","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib214","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1601-183X.2009.00529.x","article-title":"Genetic loss of d-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice","volume":"9","author":"Labrie","year":"2010","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib215","first-page":"1028","article-title":"D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123l-iodobenzamide SPECT study","volume":"46","author":"La Foug\u00e8re","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib216","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1601-183X.2010.00603.x","article-title":"Translating mouse vocalizations: prosody and frequency modulation","volume":"10","author":"Lahvis","year":"2011","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib217","doi-asserted-by":"crossref","DOI":"10.2174\/1381612819666140110122750","article-title":"Assessing schizophrenia-relevant cognitive and social deficits in mice: a selection of mouse behavioral tasks and potential therapeutic compounds","author":"Lai","year":"2014","journal-title":"Curr. Pharm. Des. Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib218","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamapsychiatry.2013.2159","article-title":"Add-on treatment of benzoate for chizophrenia: a randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitor","volume":"70","author":"Lane","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib219","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145709990939","article-title":"A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia","volume":"13","author":"Lane","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib220","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.neuron.2012.06.016","article-title":"Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia model","volume":"75","author":"Lee","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib221","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.neubiorev.2011.09.001","article-title":"Genome wide association studies (GWAS) and copy number variation (CNV) studies of the major psychoses: what have we learnt?","volume":"36","author":"Lee","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib222","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2013.01.001","article-title":"Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind, placebo controlled pilot study","volume":"145","author":"Lee","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib223","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/sj.npp.1300722","article-title":"Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin","volume":"30","author":"Lee","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib224","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.brainres.2007.04.042","article-title":"Prenatal stress generates deficits in rat social behavior: reversal by oxytocin","volume":"1156","author":"Lee","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib225","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2012.11.029","article-title":"Extensive white matter abnormalities in patients with first-episode schizophrenia: a Diffusion Tensor Imaging (DTI) study","volume":"143","author":"Lee","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib226","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1017\/S0033291711000031","article-title":"Emotional face processing and flat affect in schizophrenia: functional and structural neural correlates","volume":"41","author":"Lepage","year":"2011","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib227","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00213-002-1092-4","article-title":"Deficits in reward sensitivity in a neurodevelopmental rat model of schizophrenia","volume":"161","author":"Le Pen","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib228","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/npp.2010.156","article-title":"Cognitive control deficits in schizophrenia: mechanisms and meaning","volume":"36","author":"Lesh","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib229","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1017\/S1461145704004109","article-title":"Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials","volume":"7","author":"Leucht","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib230","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib231","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib232","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib233","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/cercor\/bhj043","article-title":"Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits","volume":"16","author":"Levy","year":"2006","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib234","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.2174\/138161212802884843","article-title":"Anandamide dysfunction in prodromal and established psychosis","volume":"18","author":"Leweke","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib235","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib236","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/j.1460-9568.2012.08156.x","article-title":"Cortical circuit dysfunction and cognitive deficits in schizophrenia \u2013 implications for preemptive interventions","volume":"35","author":"Lewis","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib237","doi-asserted-by":"crossref","first-page":"12107","DOI":"10.1073\/pnas.1109718108","article-title":"D2 receptor overexpression in the striatum leads to a deficit in inhibitory transmission and dopamine sensitivity in mouse prefrontal cortex","volume":"108","author":"Li","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib238","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2013.02.009","article-title":"Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia","volume":"146","author":"Lin","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib239","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/schbul\/sbr066","article-title":"Negative symptoms and social cognition: identifying targets for psychological interventions","volume":"37","author":"Lincoln","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib240","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2013.03.019","article-title":"A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities","volume":"147","author":"Lindenmayer","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib241","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2014.01.011","article-title":"Minocylcine supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial","author":"Liu","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib242","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1179\/016164105X35602","article-title":"Oxytocin receptors in brain cortical regions are reduced in haploinsufficient (+\/\u2212) reeler mice","volume":"27","author":"Liu","year":"2005","journal-title":"Neurol. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib243","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-007-0934-5","article-title":"Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex","volume":"196","author":"Loiseau","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib244","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00213-010-1779-x","article-title":"Analysis of licking microstructure provides no evidence for a reduction in reward value following acute or sub-chronic phencyclidine administration","volume":"209","author":"Lydall","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib245","doi-asserted-by":"crossref","first-page":"e56053","DOI":"10.1371\/journal.pone.0056053","article-title":"Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice","volume":"8","author":"Ma","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib246","doi-asserted-by":"crossref","first-page":"e75955","DOI":"10.1371\/journal.pone.0075955","article-title":"Assessing social engagement in heterogeneous groups of zebrafish: a new paradigm for autism-like behavioral responses","volume":"8","author":"Maaswinkel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib247","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.schres.2012.02.017","article-title":"Social cognition and quality of life in schizophrenia","volume":"137","author":"Maat","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib248","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pscychresns.2010.04.016","article-title":"White matter volume abnormalities and associations with symptomatology in schizophrenia","volume":"183","author":"Makris","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib249","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.euroneuro.2013.10.018","article-title":"Negative symptoms, past and present: a historical perspective and moving to DSM-5","volume":"24","author":"Malaspina","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib250","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.cell.2012.02.039","article-title":"CNVs: Harbingers of a rare variant revolution in psychiatric genetics","volume":"148","author":"Malhotra","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib251","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fnhum.2013.00216","article-title":"Insular dysfunction reflects altered between-network connectivity and severity of negative symptoms in schizophrenia during psychotic remission","volume":"7","author":"Manoliu","year":"2013","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib252","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.euroneuro.2013.10.016","article-title":"Defining and measuring negative symptoms of schizophrenia in clinical trials","volume":"24","author":"Marder","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib253","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.neubiorev.2013.08.007","article-title":"Measuring reinforcement learning and motivation constructs in experimental animals: relevance to the negative symptoms of schizophrenia","volume":"37","author":"Markou","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib254","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2011.02.006","article-title":"An animal model of schizophrenia based on chronic LSD administration: old idea, new results","volume":"61","author":"Marona-Lewicka","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib255","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neuroscience.2011.06.076","article-title":"Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence","volume":"191","author":"Marx","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib256","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2165\/00023210-200620100-00005","article-title":"Children with schizophrenia: clinical picture and pharmacological treatment","volume":"20","author":"Masi","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib257","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.brainres.2005.06.035","article-title":"N-1900, an arginine-vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: therapeutic implications for schizophrenia","volume":"1053","author":"Matsuoka","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib258","doi-asserted-by":"crossref","first-page":"e1944","DOI":"10.1371\/journal.pone.0001944","article-title":"Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study","volume":"3","author":"Matsuzawa","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib259","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s11682-013-9223-6","article-title":"Dysfunctional neuronal networks associated with impaired social interactions in early psychosis: an ICA analysis","volume":"7","author":"Mazza","year":"2013","journal-title":"Brain Imaging Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib260","doi-asserted-by":"crossref","first-page":"e62189","DOI":"10.1371\/journal.pone.0062189","article-title":"The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex","volume":"8","author":"McTighe","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib261","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/emmm.201201410","article-title":"5-HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia","volume":"4","author":"Meffre","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib262","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2013.05.009","article-title":"Social and neuro-cognition as distinct cognitive factors in schizophrenia: a systematic review","volume":"148","author":"Mehta","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib263","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cpr.2010.09.002","article-title":"Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research","volume":"31","author":"Mehta","year":"2011","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib264","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2008-1076727","article-title":"Striatal D2\/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study","volume":"41","author":"Meisenzahl","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-642-25761-2_4","article-title":"Serotonergic mechanisms as targets for existing and novel antipsychotics","volume":"212","author":"Meltzer","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib266","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cpr.2010.09.002","article-title":"Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research","volume":"31","author":"Messinger","year":"2011","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib267","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.pneurobio.2009.10.018","article-title":"Epidemiology-driven neurodevelopmental animal models of schizophrenia","volume":"90","author":"Meyer","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib268","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn3044","article-title":"Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine","volume":"12","author":"Meyer-Lindenberg","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib269","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbr.2012.07.021","article-title":"The BTBR T+ tf\/J mouse model for autism spectrum disorders-in search of biomarkers","volume":"251","author":"Meyza","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00213-005-2199-1","article-title":"NMDA receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives","volume":"179","author":"Millan","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib271","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2005.11.006","article-title":"Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application","volume":"110","author":"Millan","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib272","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","article-title":"From the cell to the clinic: a comparative review of the partial D2\/D3 receptor agonist and \u03b12-adrenoceptor antagonist, piribedil, in the treatment of Parkinson\u2019s disease","volume":"128","author":"Millan","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib273","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuropharm.2012.11.015","article-title":"An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy","volume":"68","author":"Millan","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib274","first-page":"141","article-title":"Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib275","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.neubiorev.2013.09.012","article-title":"Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative","volume":"37","author":"Millan","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib276","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2515\/therapie:2008041","article-title":"Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D3>D2 antagonist, S33138","volume":"63","author":"Millan","year":"2008","journal-title":"Therapie"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib277","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1046\/j.1460-9568.1999.00858.x","article-title":"Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat","volume":"11","author":"Millan","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib278","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-3565(24)35260-7","volume":"292","author":"Millan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib279","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","article-title":"Selective blockade of dopamine D3 vs D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis","volume":"100","author":"Millan","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib280","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1755-5949.2010.00161.x","article-title":"The role of dopamine in symptoms and treatment of apathy in Alzheimer\u05f3s disease","volume":"17","author":"Mitchell","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib281","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib282","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40263-012-0022-1","article-title":"Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study","volume":"27","author":"Modabbernia","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib283","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.pnpbp.2003.09.006","article-title":"Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality","volume":"27","author":"M\u00f6ller","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib284","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3109\/15622975.2012.677547","article-title":"Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study","volume":"14","author":"Montag","year":"2013","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib285","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1177\/0269881113503506","article-title":"Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways","volume":"27","author":"Monte","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib286","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.coph.2004.08.008","article-title":"PCP: from pharmacology to modelling schizophrenia","volume":"5","author":"Morris","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib287","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/mp.2011.75","article-title":"Disambiguating ventral striatum fMRI-related BOLD signal during expected reward prediction in schizophrenia","volume":"235","author":"Morris","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib288","first-page":"1049","article-title":"Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomized controlled trial","volume":"42","author":"Morrison","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib289","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.euroneuro.2013.11.004","article-title":"Evaluating negative-symptom-like behavioural changes in developmental models in schizophrenia","volume":"24","author":"Moser","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib290","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/npp.2012.171","article-title":"Occupancy of brain dopamine D3 receptors and drug craving: a translational approach","volume":"38","author":"Mugnaini","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib291","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pnpbp.2012.11.008","article-title":"Anti-inflammatory treatment in schizophrenia","volume":"42","author":"M\u00fcller","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib292","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbr.2007.03.003","article-title":"Hypofonctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling","volume":"180","author":"Murai","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib293","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2006.07.002","article-title":"Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review","volume":"88","author":"Murphy","year":"2006","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.euroneuro.2014.03.008_bib1111","first-page":"112","article-title":"The drive to strive: goal generation based on current needs","volume":"Jun 27","author":"Murray","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib294","first-page":"649","article-title":"The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians","volume":"23","author":"Naber","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib295","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.biopsych.2012.03.002","article-title":"Social dominance in female monkeys: dopamine receptor functions and cocaine reinforcement","volume":"72","author":"Nader","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib296","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bbr.2011.07.049","article-title":"Effects of antipsychotics on the behavioral deficits in human dominant-negative DISC1 transgenic mice with neonatal poly l:C treatment","volume":"225","author":"Nagai","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib297","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1254\/jphs.12142FP","article-title":"d-serine ameliorates neonatal Poly l:C treatment-induced emotional and cognitive impairments in adult mice","volume":"120","author":"Nagai","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib298","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2008.06.015","article-title":"Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects","volume":"105","author":"Nakagami","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib299","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","article-title":"The potential role of dopamine D3 receptor neurotransmission in cognition","volume":"23","author":"Nakajima","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbr.2013.04.012","article-title":"Effects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets","volume":"249","author":"Nakako","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib301","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fpsyt.2013.00016","article-title":"Gray matter changes in subjects at high risk for developing psychosis and first-episode schizophrenia: a voxel-based structural MRI study","volume":"4","author":"Nakamura","year":"2013","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib302","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.psychres.2007.10.008","article-title":"A two-factor structure for the schedule for the deficit syndrome in schizophrenia","volume":"158","author":"Nakaya","year":"2008","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib303","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib304","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.euroneuro.2013.09.011","article-title":"Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans","volume":"24","author":"Neill","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib305","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.jpsychires.2012.08.026","article-title":"Glutamate receptor \u03b4 1 (GRID1) genetic variation and brain structure in schizophrenia","volume":"46","author":"Nenadic","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib306","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11682-012-9193-0","article-title":"Neuropsychological variability, symptoms, and brain imaging in chronic schizophrenia","volume":"7","author":"Nestor","year":"2013","journal-title":"Brain Imaging Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib307","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.02.007","article-title":"Alterations of the brain reward system in antipsychotic na\u00efve schizophrenia patients","volume":"71","author":"Nielsen","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib308","doi-asserted-by":"crossref","first-page":"e66695","DOI":"10.1371\/journal.pone.0066695","article-title":"Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats","volume":"8","author":"Nikiforuk","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib309","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1752-0509-7-30","article-title":"Impaired coupling of local and global functional feedbacks underlies abnormal synchronization and negative symptoms of schizophrenia","volume":"7","author":"Noh","year":"2013","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib310","doi-asserted-by":"crossref","unstructured":"Nordentoft, M., Melau, M., Iversen, T., Petersen, L., Jeppesen, P., Thorup, A., Bartelsen, M., Hjorthoj, C.R., Hastrup, L.H., Jorgensen, P., 2014. From research to practice: how OPUS treatment was accepted and implemented throughout Denmark. Early Interv. Psychiatry, 10.1111\/eip.12108","DOI":"10.1111\/eip.12108"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib311","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fncir.2013.00079","article-title":"Toward developmental models of psychiatric disorders in zebrafish","volume":"7","author":"Norton","year":"2013","journal-title":"Front. Neural Circuits"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib312","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1185\/03007990903576953","article-title":"Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride","volume":"26","author":"Nuss","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib313","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.01.015","article-title":"Early and late stages of visual processing in individuals in prodromal state and first episode schizophrenia: an ERP study","volume":"146","author":"Oribe","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib314","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.schres.2013.05.007","article-title":"Links among resting-state default-mode network, salience network, and symptomatology in schizophrenia","volume":"148","author":"Orliac","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib315","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neuroscience.2007.03.051","article-title":"Phenotypic characterization of spatial cognition and social behavior in mice with \u2018knockout\u2019 of the schizophrenia risk gene neuregulin 1","volume":"147","author":"O\u05f3Tuathaigh","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib316","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.euroneuro.2013.08.009","article-title":"Genetically modified mice related to schizophrenia and other psychoses: seeking phenotypic insights into the pathobiology and treatment of negative symptoms","volume":"24","author":"O\u2019Tuathaigh","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib317","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.schres.2008.05.017","article-title":"Reduction of auditory event-related P300 amplitude in subjects with at-risk mental state for schizophrenia","volume":"105","author":"Ozg\u00fcrdal","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib318","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1749-6632.2011.06262.x","article-title":"The orbitofrontal cortex and the computation of subjective value: consolidated concepts and new perspectives","volume":"1239","author":"Padoa-Schioppa","year":"2011","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib319","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1176\/appi.ajp.161.1.53","article-title":"Social anxiety in outpatients with schizophrenia: a relevant cause of disability","volume":"161","author":"Pallanti","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib320","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2012.06.029","article-title":"Synaptic and extrasynaptic NMDA receptors are gated by different endogenous co-agonists","volume":"150","author":"Papouin","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib321","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pscychresns.2008.03.010","article-title":"Medial prefrontal default-mode hypoactivity affecting trait physical anhedonia in schizophrenia","volume":"171","author":"Park","year":"2009","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib1112","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pbb.2010.05.016","article-title":"Hedonic and motivational roles of opioids in food reward: implications for overeating disorders","volume":"97","author":"Peci\u00f1a","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib322","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2011.07.027","article-title":"Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia","volume":"132","author":"Pedersen","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib323","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pneurobio.2010.10.003","article-title":"Modulation of cortical excitability induced by repetitive transcranial magnetic stimulation: influence of timing and geometrical parameters and underlying mechanisms","volume":"93","author":"Pell","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib324","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00406-004-0464-7","article-title":"The deficit syndrome of the psychotic illness. A clinical and nosological study","volume":"254","author":"Peralta","year":"2004","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib325","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbs152","article-title":"Characterisation of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs","volume":"40","author":"Peralta","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib326","doi-asserted-by":"crossref","first-page":"e1360","DOI":"10.1371\/journal.pone.0001360","article-title":"An animal model of emotional blunting in schizophrenia","volume":"12","author":"Pietersen","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib327","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/schbul\/sbq165","article-title":"Dysfunctional thalamus-related networks in schizophrenia","volume":"37","author":"Pinault","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib328","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.neuropharm.2011.04.019","article-title":"Tracing the development of psychosis and its prevention: what can be learned from animal models","volume":"62","author":"Piontkewitz","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib329","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.psychres.2012.02.018","article-title":"Negative symptoms in individuals at clinical high risk of psychosis","volume":"195","author":"Piskutic","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib330","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nm.2315","article-title":"Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors","volume":"17","author":"Pitcher","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib331","article-title":"Mice gamble for food: individual differences in risky choices and prefrontal cortex serotonin","author":"Pittaras","year":"2014","journal-title":"J. Addict. Res. Ther."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib332","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.yhbeh.2011.10.010","article-title":"Oxytocin receptor knockout mice display deficits in the expression of autism-related behaviors","volume":"61","author":"Pobbe","year":"2012","journal-title":"Horm. Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib333","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/02643294.2012.710600","article-title":"The maps problem and the mapping problem: two challenges for a cognitive neuroscience of speech and language","volume":"29","author":"Poeppel","year":"2012","journal-title":"Cogn. Neuropsychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib334","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/mp.2013.136","article-title":"Imaging glutamate in schizophrenia: review of findings and implications for drug discovery","volume":"19","author":"Poels","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib335","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1176\/appi.ajp.159.2.227","article-title":"A PET study of the pathophysiology of negative symptoms in schizophrenia","volume":"159","author":"Potkin","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib336","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.schres.2013.08.024","article-title":"Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis","volume":"150","author":"Potkin","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib337","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3649","article-title":"Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap","volume":"11","author":"Pratt","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib338","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/YCT.0b013e318270295f","article-title":"Can repetitive transcranial magnetic stimulation be considered effective treatment option for negative symptoms of schizophrenia","volume":"29","author":"Prikryl","year":"2013","journal-title":"J. ECT"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib339","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.schres.2013.06.015","article-title":"A detailed analysis of the effect of repetitive transcranial magnetic stimulation on negative symptoms of schizophrenia: a double-blind trial","author":"Prikryl","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib340","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature12975","article-title":"A polygenic burden of rare disruptive mutations in schizophrenia","volume":"506","author":"Purcell","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib341","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/ern.09.142","article-title":"Progressive structural brain changes in schizophrenia","volume":"10","author":"Puri","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib342","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4088\/JCP.08m04845yel","article-title":"Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the positive and negative syndrome scale","volume":"71","author":"Rapado-Castro","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib343","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/mp.2012.23","article-title":"Neurodevelopmental model of schizophrenia: update 2012","volume":"17","author":"Rapoport","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib344","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.biopsych.2010.04.013","article-title":"Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia","volume":"68","author":"Reid","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib345","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/ern.10.191","article-title":"Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment","volume":"11","author":"Remington","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib346","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2009.07.016","article-title":"Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist","volume":"58","author":"Ring","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib347","doi-asserted-by":"crossref","unstructured":"Ritsner, M.S., Bawakny, H., Kreinin, A., 2014. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized, add-on, two-center trial. Psychiatry Clin. Neurosci. 10.1111\/pcn.12150","DOI":"10.1111\/pcn.12150"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib348","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.4088\/JCP.09m05031yel","article-title":"Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial","volume":"71","author":"Ritsner","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib349","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/schbul\/sbr072","article-title":"Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a research update","volume":"37","author":"Roder","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eurpsy.2010.08.014","article-title":"Assessment of social anxiety in first episode psychosis using the Liebowitz Social Anxiety scale as a self-report measure","volume":"26","author":"Romm","year":"2011","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib351","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/schbul\/sbq015","article-title":"Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia","volume":"37","author":"Rosenfeld","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib352","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/schbul\/sbs092","article-title":"In vivo measurements of glutamate, GABA, and NAAG in schizophrenia","volume":"39","author":"Rowland","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib353","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2010.09.014","article-title":"Peripheral oxytocin is associated with reduced symptom severity in schizophrenia","volume":"124","author":"Rubin","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib354","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-004-1897-4","article-title":"Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia","volume":"176","author":"Rueter","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib355","first-page":"CD005581","article-title":"Antidepressants for the negative symptoms of schizophrenia","volume":"3","author":"Rummel","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib356","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/neuro.09.036.2009","article-title":"Is there a degerative process going on in the brain of people with schizophrenia?","volume":"3","author":"Rund","year":"2009","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib357","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.schres.2012.11.014","article-title":"A brief cognitive-behavioural social skills training for stabilised outpatients with schizophrenia: a preliminary study","volume":"143","author":"Rus-Calafell","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib358","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.conb.2012.11.013","article-title":"Are there specialized circuits for social cognition and are they unique to humans?","volume":"23","author":"Rushworth","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib359","first-page":"82","article-title":"Preventive pharmacological treatment \u2013 an evolving new concept in schizophrenia","volume":"48","author":"Sabbag","year":"2011","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib360","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2174\/1381612811319140002","article-title":"d-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy","volume":"19","author":"Sacchi","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib361","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2826.2012.02385.x","article-title":"Mice heterozygous for the oxytocin receptor gene (Oxtr(+\/\u2212)) show impaired social behaviour but not increased aggression or cognitive inflexibility: evidence of a selective haploinsufficiency gene effect","volume":"25","author":"Sala","year":"2013","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib362","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1901\/jeab.2012.97-125","article-title":"The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond","volume":"97","author":"Salamone","year":"2012","journal-title":"J. Exp. Anal. Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib363","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00008877-199501000-00009","article-title":"Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats","volume":"6","author":"Sams-Dodd","year":"1995","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib364","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/schbul\/sbt057","article-title":"Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial","volume":"40","author":"Sanchez","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib365","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archpsyc.57.5.471","article-title":"Volumetric measures of the frontal and temporal lobe regions in schizophrenia-relationship to negative symptoms","volume":"57","author":"Sanfilipo","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib366","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cub.2012.10.018","article-title":"Enhancing social ability by stimulating right temporoparietal junction","volume":"22","author":"Santiesteban","year":"2012","journal-title":"Curr. Biol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib367","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/08039488.2011.577188","article-title":"Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials","volume":"65","author":"Sarin","year":"2011","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib368","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2012.06.016","article-title":"Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia","volume":"139","author":"Sasayama","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib369","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbr.2012.12.028","article-title":"Reduced social interaction, behavioural flexibility and BDNF signalling in the BTBR T+ tf\/J strain, a mouse model of autism","volume":"251","author":"Scattoni","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib370","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrn2213","article-title":"Remembering the past to imagine the future: the prospective brain","volume":"8","author":"Schacter","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib371","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","article-title":"Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver","volume":"78","author":"Schobel","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib372","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2009.07.016","article-title":"Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia","volume":"114","author":"Schobel","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib373","doi-asserted-by":"crossref","first-page":"19384","DOI":"10.1523\/JNEUROSCI.1979-13.2013","article-title":"Long-term antagonism of \u03ba opioid receptors prevents escalation of and increased motivation for heroin intake","volume":"33","author":"Scholsburg","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib374","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbr.2005.11.005","article-title":"Behavioural effects of neonatal lesions of the medial prefrontal cortex and subchronic pubertal treatment with phencyclidine of adult rats","volume":"168","author":"Schwabe","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib375","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrn3257","article-title":"Kynurenines in the mammalian brain: when physiology meets pathology","volume":"13","author":"Schwarcz","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib376","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neuropharm.2012.07.011","article-title":"Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain","volume":"64","author":"Scoriels","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib377","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbr.2011.05.034","article-title":"Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio)","volume":"224","author":"Seibt","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib378","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1017\/S146114570999023X","article-title":"Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats","volume":"13","author":"Seillier","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib379","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/npp.2013.81","article-title":"Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia","volume":"38","author":"Seillier","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib380","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.schres.2010.11.003","article-title":"Cortical regional differences of delta waves during all-night sleep in schizophrenia","volume":"126","author":"Sekimoto","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib381","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.schres.2006.09.028","article-title":"Social cognition in schizophrenia: relationships with neurocognition and negative symptoms","volume":"90","author":"Sergi","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib382","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.02.012","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia","volume":"53","author":"Shen","year":"2014","journal-title":"J. Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib383","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.psychres.2013.12.019","article-title":"Revisiting the therapeutic effect of rTMS on negative simptoms in schizophrenia: a meta-analysis","volume":"215","author":"Shi","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib384","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1017\/S1461145710001471","article-title":"SSRI augmentation of antipsychotics alters expression of GABAA receptor and related genes in PMC of schizophrenia patients","volume":"14","author":"Silver","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib385","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nrn2851","article-title":"Behavioural phenotyping assays for mouse models of autism","volume":"11","author":"Silverman","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib386","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.schres.2009.11.007","article-title":"Neural correlates of reward processing in schizophrenia-relationship to apathy and depression","volume":"118","author":"Simon","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib387","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.biopsych.2011.01.012","article-title":"Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia","volume":"69","author":"Simpson","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib388","doi-asserted-by":"crossref","unstructured":"Simpson, E.H., Winiger, V., Biezonski, D.K., Haq, I., Kandel, E.R., Kellendonk, C., 2014. Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition Biol. Psychiatry, 10.1016\/j.biopsych.2013.11.023","DOI":"10.1016\/j.biopsych.2013.11.023"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib389","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia","volume":"25","author":"Singh","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib390","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/bjp.bp.109.067710","article-title":"Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis","volume":"197","author":"Singh","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib391","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/hbm.21360","article-title":"Different duration of at-risk mental state associated with neurofunctional abnormalities. A multimodal imaging study","volume":"33","author":"Smieskova","year":"2012","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib392","doi-asserted-by":"crossref","first-page":"10695","DOI":"10.1523\/JNEUROSCI.2178-07.2007","article-title":"Maternal immune activation alters fetal brain development through interleukin-6","volume":"27","author":"Smith","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib393","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","article-title":"Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review","volume":"38","author":"Sommer","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib394","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.2174\/138920112800784925","article-title":"Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies","volume":"13","author":"Stan","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib395","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/mds.22577","article-title":"The syndromal validity and nosological position of apathy in Parkinson\u2019s disease","volume":"24","author":"Starkstein","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib396","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjuntive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib397","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3233\/JAD-131385","article-title":"Neurobiological correlates of apathy in Alzheimer\u2019s disease and mild cognitive impairment: a critical review","volume":"39","author":"Stella","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib398","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pnpbp.2004.08.015","article-title":"Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia","volume":"29","author":"Stip","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib399","doi-asserted-by":"crossref","first-page":"RC157","DOI":"10.1523\/JNEUROSCI.21-15-j0003.2001","article-title":"Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus","volume":"21","author":"Stratella","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib400","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jpsychires.2013.01.015","article-title":"Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome","volume":"47","author":"Strauss","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib401","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2012.10.012","article-title":"Next-generation negative symptom assessment for clinical trials: validation of the brief negative symptom scale","volume":"142","author":"Strauss","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib402","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1093\/schbul\/sbt197","article-title":"A review of reward processing and motivational impairment in schizophrenia","volume":"40","author":"Strauss","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib403","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrg3240","article-title":"Genetic architectures of psychiatric disorders: the emerging picture and its implications","volume":"13","author":"Sullivan","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib404","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/hmg\/ddp086","article-title":"Sept5 deficiency exerts pleiotropic influence on affective behaviors and cognitive functions in mice","volume":"18","author":"Suzuki","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib405","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/npp.2013.38","article-title":"Deficiency of Schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia","volume":"38","author":"Takao","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib406","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.schres.2013.07.036","article-title":"Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia","volume":"150","author":"Takayanagi","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib407","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2010.05.006","article-title":"Volume reduction and altered sulco-gyral pattern of the orbitofrontal cortex in first-episode schizophrenia","volume":"121","author":"Takayanagi","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib1113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0079-6123(09)17910-4","article-title":"The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research","volume":"179","author":"Talbot","year":"2009","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib408","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib409","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/npp.2013.300","article-title":"Abnormal GABAergic function and negative affect in schizophrenia","volume":"29","author":"Taylor","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib410","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2011.09.007","article-title":"Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia","volume":"71","author":"Taylor","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib411","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugalcdep.2008.02.013","article-title":"Social reward-conditioned place preference: a model revealing an interaction between cocaine and social context rewards in rats","volume":"96","author":"Thiel","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib412","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.schres.2004.07.001","article-title":"M50 sensory gating predicts negative symptoms in schizophrenia","volume":"73","author":"Thoma","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib413","doi-asserted-by":"crossref","first-page":"e6598","DOI":"10.1371\/journal.pone.0006598","article-title":"Worth the EEfRT? The effort expenditure for rewards task as an objective measure of motivation and anhedonia","volume":"4","author":"Treadway","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib414","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1037\/a0028813","article-title":"Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia","volume":"121","author":"Treadway","year":"2012","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib1114","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euroneuro.2008.03.001","article-title":"Cannabinoid and opioid modulation of social play behavior in adolescent rats: differential behavioral mechanisms","volume":"18","author":"Trezza","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib415","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.dcn.2011.05.007","article-title":"Evaluating the rewarding nature of social interactions in laboratory animals","volume":"1","author":"Trezza","year":"2011","journal-title":"Dev. Cogn. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib416","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1523\/JNEUROSCI.5492-10.2011","article-title":"Nucleus accumbens \u03bc-opioid receptors mediate social reward","volume":"31","author":"Trezza","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib417","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mp.2013.57","article-title":"Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation","volume":"18","author":"Trifilieff","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib418","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbr.2008.11.039","article-title":"The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia","volume":"204","author":"Tseng","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib419","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pbb.2007.07.005","article-title":"Subchronic phencyclidine exposure potentiates the behavioral and c-Fos response to stressful stimuli in rats","volume":"88","author":"Turgeon","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib420","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1369-1600.2007.00070.x","article-title":"Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade","volume":"12","author":"Tzschentke","year":"2007","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib421","unstructured":"Umbricht, D., Yoo, K., Youssef, E., Dorflinger, E., Martin-Facklam, M., Bausch, A., Arrowsmith, R., Alberati, D., Marder, S.R., Santarelli, L., 2010. Glycine Transporter Type 1 (GLYT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. In: Proceedings of the ACNP 49th Annual Meeting, Miami Beach, FL."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib422","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/schbul\/sbt077","article-title":"Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction","volume":"40","author":"Unschuld","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib423","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1176\/appi.ajp.2010.09081215","article-title":"Prefrontal cortical deficits and impaired cognition-emotion interactions in schizophrenia","volume":"168","author":"Ursu","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib424","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.jpsychires.2013.09.006","article-title":"The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia","volume":"47","author":"Valencia","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib425","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2010.07.004","article-title":"Left dorsolateral prefrontal cortex dysfunction in medication-na\u00efve schizophrenia","volume":"123","author":"Van Veelen","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib426","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pbb.2010.01.010","article-title":"MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?Pharmacology","volume":"95","author":"Vardigan","year":"2010","journal-title":"Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib427","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/jnr.22753","article-title":"Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia","volume":"90","author":"V\u00e1zquez-Roque","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib428","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/syn.21718","article-title":"Chronic cerebrolysin administration attenuates neuronal abnormalities in the basolateral amygdala induced by neonatal ventral hippocampus lesion in the rat","volume":"68","author":"Vazquez-Roque","year":"2014","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib429","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1038\/tp.2012.116","article-title":"Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies","volume":"2","author":"Vita","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib430","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.schres.2009.03.035","article-title":"Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis","volume":"113","author":"Ventura","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib431","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.schres.2005.01.001","article-title":"The association between social anxiety and social functioning in first episode psychosis","volume":"76","author":"Voges","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib432","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jamapsychiatry.2013.786","article-title":"Neuroimaging evidence for the deficit subtype of schizophrenia","volume":"70","author":"Voineskos","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib433","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.pnpbp.2012.02.003","article-title":"Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia","volume":"37","author":"Volpe","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib434","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/brain\/awt094","article-title":"Dissecting the uncinate fasciculus: disorders, controversies and a hypothesis","volume":"136","author":"Von Der Heide","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib435","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/npp.2008.214","article-title":"Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers","volume":"34","author":"Waltz","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib436","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1152\/physrev.00035.2008","article-title":"Neurophysiological and computational principles of cortical rhythms in cognition","volume":"90","author":"Wang","year":"2010","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib437","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1037\/a0016503","article-title":"Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits","volume":"123","author":"Ward","year":"2009","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib438","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.beproc.2011.02.004","article-title":"Modeling motivational deficits in mouse models of schizophrenia: behavior analysis as a guide for neuroscience","volume":"87","author":"Ward","year":"2011","journal-title":"Behav. Processes"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib439","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/npp.2012.15","article-title":"Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia","volume":"37","author":"Ward","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib440","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/npp.2011.254","article-title":"Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex","volume":"37","author":"Watson","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib1115","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11200860-000000000-00000","article-title":"Asenapine","volume":"23","author":"Weber","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib441","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.4088\/JCP.11m07031","article-title":"A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia","volume":"73","author":"Weiser","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib443","first-page":"49","article-title":"Default mode network activity and connectivity in psychopathology","volume":"8","author":"Whitfield-Gabrieli","year":"2012","journal-title":"Annu. Rev. Rev. Psychol"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib444","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.euroneuro.2013.11.008","article-title":"Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia","volume":"24","author":"Wilson","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib445","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0024-3205(00)00934-6","article-title":"Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists. A link between the glutamatergic and serotonergic hypothesis of schizophrenia","volume":"68","author":"Winter","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib446","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib447","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00441-013-1607-9","article-title":"Affective communication in rodents ultrasonic vocalization as a tool for research on emotion and motivation","volume":"354","author":"W\u00f6hr","year":"2013","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib448","doi-asserted-by":"crossref","first-page":"e51455","DOI":"10.1371\/journal.pone.0051455","article-title":"Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib449","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1176\/appi.ajp.2010.10060855","article-title":"A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes","volume":"168","author":"Wykes","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib450","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijpsycho.2010.05.009","article-title":"Impaired anticipatory event-related potentials in schizophrenia","volume":"77","author":"Wynn","year":"2010","journal-title":"Int. J. Psychophysiol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib451","doi-asserted-by":"crossref","first-page":"e32969","DOI":"10.1371\/journal.pone.0032969","article-title":"Deletion of glutamate delta-1 receptor in mouse leads to aberrant emotional and social behaviors","volume":"7","author":"Yadav","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib452","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pscychresns.2004.05.004","article-title":"Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study","volume":"131","author":"Yamasue","year":"2004","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.euroneuro.2014.03.008_bib453","first-page":"159","article-title":"Male mice emit distinct ultrasonic vocalizations when the female leaves the social interaction arena","volume":"19","author":"Yang","year":"2013","journal-title":"Front Behav Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib454","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/ars.2010.3603","article-title":"Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view","volume":"15","author":"Yao","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib455","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1037\/a0018475","article-title":"Integrity of emotional and motivational states during the prodromal, first-episode, and chronic phases of schizophrenia","volume":"119","author":"Yee","year":"2010","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib456","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/syn.20830","article-title":"A behavioral and molecular analysis of ketamine in zebrafish","volume":"65","author":"Zakhary","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2014.03.008_bib457","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF02191800","article-title":"Neuropsychology of schizophrenia according to Kraepelin: disorders of volition and executive functioning","volume":"245","author":"Zec","year":"1995","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib458","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00406-007-0793-4","article-title":"White matter alterations in schizophrenic patients with pronounced negative sympomatology and with positive family history for schizophrenia","volume":"258","author":"Zetzsche","year":"2008","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib459","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.008_bib460","doi-asserted-by":"crossref","unstructured":"Zhu, F., Zhang, L., Ding, Y.Q., Zheng, Y., Zhao, J., 2014. Neonatal intrahippocampal injection of lipopolysaccharide induces deficits in social behavior and prepulse inhibition and microglial activation in rats: implication for a new schizophrenia animal model. Brain Behav. Immun. 10.1016\/j.bbi.2014.01.017","DOI":"10.1016\/j.bbi.2014.01.017"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14000935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14000935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:35:24Z","timestamp":1746171324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":467,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0924977X14000935"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.03.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and ECNP.","name":"copyright","label":"Copyright"}]}}